PlumX Metrics
Embed PlumX Metrics

Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy

Clinical Cancer Research, ISSN: 1557-3265, Vol: 21, Issue: 14, Page: 3196-3203
2015
  • 447
    Citations
  • 0
    Usage
  • 314
    Captures
  • 3
    Mentions
  • 2
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    447
    • Citation Indexes
      441
    • Clinical Citations
      3
      • PubMed Guidelines
        3
    • Policy Citations
      3
      • Policy Citation
        3
  • Captures
    314
  • Mentions
    3
    • Blog Mentions
      1
      • Blog
        1
    • News Mentions
      1
      • News
        1
    • References
      1
      • Wikipedia
        1
  • Social Media
    2
    • Shares, Likes & Comments
      2
      • Facebook
        2

Most Recent News

Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma

STUDY INFORMATION OFFICIAL TITLE: Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma CURRENT STATUS: Recruiting: 2 Years STUDY TYPE:

Article Description

Purpose: Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and blood samples from the FASTACT-2 study. Experimental Design: Patients were randomized to receive six cycles of gemcitabine/platinum plus sequential erlotinib or placebo. EGFR mutation testing was performed using the cobas tissue test and the cobas blood test (in development). Blood samples at baseline, cycle 3, and progression were assessed for blood test detection rate, sensitivity, and specificity; concordance with matched tumor analysis (n = 238), and correlation with progressionfree survival (PFS) and overall survival (OS). Results: Concordance between tissue and blood tests was 88%, with blood test sensitivity of75%and a specificity of 96%. Median PFS was 13.1 versus 6.0 months for erlotinib and placebo, respectively, for those with baseline EGFR mut+ cfDNA [HR, 0.22; 95% confidence intervals (CI), 0.14-0.33, P < 0.0001] and 6.2 versus 6.1 months, respectively, for the EGFR mut cfDNA subgroup (HR, 0.83;95%CI, 0.65-1.04, P=0.1076). For patients with EGFR mut+ cfDNA at baseline, median PFS was 7.2 versus 12.0 months for cycle 3 EGFR mut+ cfDNA versus cycle 3 EGFR mut patients, respectively (HR, 0.32; 95% CI, 0.21-0.48, P < 0.0001); median OS by cycle 3 status was 18.2 and 31.9 months, respectively (HR, 0.51; 95% CI, 0.31-0.84, P = 0.0066). Conclusions: Blood-based EGFR mutation analysis is relatively sensitive and highly specific. Dynamic changes in cfDNA EGFR mutation status relative to baseline may predict clinical outcomes.

Bibliographic Details

Mok, Tony; Wu, Yi-Long; Lee, Jin Soo; Yu, Chong-Jen; Sriuranpong, Virote; Sandoval-Tan, Jennifer; Ladrera, Guia; Thongprasert, Sumitra; Srimuninnimit, Vichien; Liao, Meilin; Zhu, Yunzhong; Zhou, Caicun; Fuerte, Fatima; Margono, Benjamin; Wen, Wei; Tsai, Julie; Truman, Matt; Klughammer, Barbara; Shames, David S; Wu, Lin

American Association for Cancer Research (AACR)

Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know